Dowpharma has a 30-year record of secure, timely and compliant supply of APIs and intermediates. The differentiated technology and full service offerings enable Dowpharma to support both big pharmaceutical and small and emerging (virtual) companies alike. Virtual pharmaceutical companies can especially benefit from proven capabilities around process scale-up, analytical development, validation and regulatory support. Core technology offerings from Dowpharma support the preparation of chiral intermediates (RSM's) and include biocatalysis, asymmetric hydrogenation (including the DuPhos catalysts), asymmetric allylic alkylation (Trost technology), asymmetric hydroformylation, crystallization-based resolution and chiral pool starting materials. Pharmaceutical and fine chemicals companies can contract Dowpharma to manufacture chiral intermediates in either cGMP or non-cGMP assets using its proprietary technology, or directly purchase catalysts and operate the process in the facilities of their choice. In addition, Dowpharma can offer products produced through its preferred Asian contract manufacturing network.